| Autor: |
Parker JC; Pfizer Inc., Central Research Division, Groton, Connecticut 06340, USA. janice_c_parker@groton.pfizer.com, VanVolkenburg MA, Nardone NA, Hargrove DM, Andrews KM |
| Jazyk: |
angličtina |
| Zdroj: |
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 1997 Jul 30; Vol. 236 (3), pp. 665-9. |
| DOI: |
10.1006/bbrc.1997.7034 |
| Abstrakt: |
The effects of selective inhibition of cyclic AMP phosphodiesterase type III on insulin and glucose levels during an oral glucose challenge were evaluated in obese, diabetic ob/ob mice and in lean, non-diabetic littermates using the selective inhibitor, milrinone. Oral administration of milrinone increased plasma insulin levels both in ob/ob and in lean mice. Glucose tolerance was improved in lean, but not in ob/ob mice, where glucose levels were increased by milrinone treatment. In isolated hepatocytes from normal rats incubation with 200 microM milrinone caused a 30% increase in glucose release with a corresponding depletion of glycogen stores. Stimulation of isolated rat adipocytes with 200 microM milrinone increased glycerol release 7-fold. We conclude that selective inhibitors of cyclic AMP phosphodiesterase III are effective insulin secretagogues, but their therapeutic utility may be limited by their concurrent stimulation of lipolysis and hepatic glucose output. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect